Therapeutic Antioxidant Supplementation
In plain words A study of IP6 in people 16 to 77, run by Superficial Siderosis Research Alliance Inc.. It plans to enroll about 50 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 16 to 77. Conditions: Superficial Siderosis.
What it tests, as registered
Inosine; IP6
Registered summary
A remotely administered study, non-randomized, non-blinded, controlled parallel assignment phase 2 trial to determine if oral inosine or inositol hexaphosphate will provide an effective long-term therapy to combat or slow neural damage progression either concurrently with existing iron chelation therapy or during the natural course of the disorder. Clinical changes in hearing, balance, and mobility, and cognition will be assessed for 36 months through patient-reported outcomes of study assigned assessments.
Where, as registered
No sites listed yet.